Related Articles for PubMed (Select 16236177)

A multicenter trial of the efficacy and safety of tigecycline versus imipenem/cilastatin in patients with complicated intra-abdominal infections [Study ID Numbers: 3074A1-301-WW; ClinicalTrials.gov Identifier: NCT00081744].

Oliva ME, Rekha A, Yellin A, Pasternak J, Campos M, Rose GM, Babinchak T, Ellis-Grosse EJ, Loh E; 301 Study Group.

BMC Infect Dis. 2005 Oct 19;5:88.

PMID: 16236177 [PubMed - indexed for MEDLINE]

Tigecycline is efficacious in the treatment of complicated intra-abdominal infections.

Fomin P, Beuran M, Gradauskas A, Barauskas G, Datsenko A, Dartois N, Ellis-Grosse E, Loh E, Three Hundred Six Study Group.

Int J Surg. 2005;3(1):35-47.

PMID: 17462257 [PubMed]

The efficacy and safety of tigecycline for the treatment of complicated intra-abdominal infections - the European experience.

Fomin P, Koalov S, Cooper A, Babinchak T, Dartois N, De Vane N, Castaing N, Tellado J; 301 And 306 Study Groups.

J Chemother. 2008 Oct;20 Suppl 1:12-9.

PMID: 19036670 [PubMed - indexed for MEDLINE]

The efficacy and safety of tigecycline for the treatment of complicated intra-abdominal infections: analysis of pooled clinical trial data.

Babinchak T, Ellis-Grosse E, Dartois N, Rose GM, Loh E; Tigecycline 301 Study Group; Tigecycline 306 Study Group.

Clin Infect Dis. 2005 Sep 1;41 Suppl 5:S354-67.

PMID: 16080073 [PubMed - indexed for MEDLINE]

Efficacy and safety of tigecycline monotherapy compared with vancomycin plus aztreonam in patients with complicated skin and skin structure infections: Results from a phase 3, randomized, double-blind trial.

Sacchidanand S, Penn RL, Embil JM, Campos ME, Curcio D, Ellis-Grosse E, Loh E, Rose G.

Int J Infect Dis. 2005 Sep;9(5):251-61.

PMID: 16099700 [PubMed - indexed for MEDLINE]

Efficacy and safety of tigecycline compared with vancomycin or linezolid for treatment of serious infections with methicillin-resistant Staphylococcus aureus or vancomycin-resistant enterococci: a Phase 3, multicentre, double-blind, randomized study.

Florescu I, Beuran M, Dimov R, Razbadauskas A, Bochan M, Fichev G, Dukart G, Babinchak T, Cooper CA, Ellis-Grosse EJ, Dartois N, Gandjini H; 307 Study Group.

J Antimicrob Chemother. 2008 Sep;62 Suppl 1:i17-28.

PMID: 18684703 [PubMed - indexed for MEDLINE]

Predictors of efficacy and health resource utilization in treatment of complicated intra-abdominal infections: evidence for pooled clinical studies comparing tigecycline with imipenem-cilastatin.

Mallick R, Sun S, Schell SR.

Surg Infect (Larchmt). 2007 Apr;8(2):159-72.

PMID: 17437361 [PubMed - indexed for MEDLINE]

Efficacy and tolerability of IV doripenem versus meropenem in adults with complicated intra-abdominal infection: a phase III, prospective, multicenter, randomized, double-blind, noninferiority study.

Lucasti C, Jasovich A, Umeh O, Jiang J, Kaniga K, Friedland I.

Clin Ther. 2008 May;30(5):868-83.

PMID: 18555934 [PubMed - indexed for MEDLINE]

Meropenem versus imipenem-cilastatin for the treatment of hospitalized patients with complicated skin and skin structure infections: results of a multicenter, randomized, double-blind comparative study.

Fabian TC, File TM, Embil JM, Krige JE, Klein S, Rose A, Melnick D, Soto NE.

Surg Infect (Larchmt). 2005 Fall;6(3):269-82.

PMID: 16201937 [PubMed - indexed for MEDLINE]

10:

Results of a multicenter, randomized, open-label efficacy and safety study of two doses of tigecycline for complicated skin and skin-structure infections in hospitalized patients.

Postier RG, Green SL, Klein SR, Ellis-Grosse EJ, Loh E; Tigecycline 200 Study Group.

Clin Ther. 2004 May;26(5):704-14.

PMID: 15220014 [PubMed - indexed for MEDLINE]

11:

A post hoc subgroup analysis of meropenem versus imipenem/cilastatin in a multicenter, double-blind, randomized study of complicated skin and skin-structure infections in patients with diabetes mellitus.

Embil JM, Soto NE, Melnick DA.

Clin Ther. 2006 Aug;28(8):1164-74.

PMID: 16982293 [PubMed - indexed for MEDLINE]

12:

A Phase 3, open-label, non-comparative study of tigecycline in the treatment of patients with selected serious infections due to resistant Gram-negative organisms including Enterobacter species, Acinetobacter baumannii and Klebsiella pneumoniae.

Vasilev K, Reshedko G, Orasan R, Sanchez M, Teras J, Babinchak T, Dukart G, Cooper A, Dartois N, Gandjini H, Orrico R, Ellis-Grosse E; 309 Study Group.

J Antimicrob Chemother. 2008 Sep;62 Suppl 1:i29-40.

PMID: 18684704 [PubMed - indexed for MEDLINE]

13:

Tigecycline: a glycylcycline antimicrobial agent.

Doan TL, Fung HB, Mehta D, Riska PF.

Clin Ther. 2006 Aug;28(8):1079-106. Review.

PMID: 16982286 [PubMed - indexed for MEDLINE]

14:

Tigecycline versus levofloxacin for the treatment of community-acquired pneumonia: European experience.

Dartois N, Castaing N, Gandjini H, Cooper A; Tigecycline 313 Study Group.

J Chemother. 2008 Oct;20 Suppl 1:28-35.

PMID: 19036672 [PubMed - indexed for MEDLINE]